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Abstract
Background: The role of eosinophils in cancer is not yet completely understood, but patients with eosinophilia
show a trend towards longer survival in several types of cancer, including melanoma. However, eosinophil count at
initial diagnosis of metastatic melanoma does not predict survival. Since eosinophil cationic protein (ECP) mediates
anticancer effects, such as tissue remodelling and cytotoxic activity, we investigated this marker as an early
prognostic marker in metastatic melanoma.
Methods: Serum of 56 melanoma patients was collected at the time of diagnosis of metastatic disease. ECP levels
as measured by ELISA were correlated with overall survival (OS) in patients before systemic therapy with
immunotherapy or chemotherapy. Statistical analyses were performed using the Log–Rank (Mantel–Cox) test.
Results: The median OS for patients with high serum ECP above 12.2 ng/ml was 12 months (n = 39), compared to
28 months for patients with ECP below this threshold (n = 17; p = 0.0642). In patients with cutaneous melanoma,
excluding patients with uveal and mucosal melanoma, the survival difference was even more striking (p = 0.0393).
ECP’s effect size on OS was observed independently of the consecutive therapy. ECP levels were not correlated
with LDH levels.
Conclusion: ECP seems to be a novel prognostic serum marker for the outcome of melanoma patients, which is
independent of LDH and easy to perform in clinical practice. The striking negative prognostic value of high ECP
level is unanticipated and can guide patient management.
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Background
Established prognostic markers in melanoma – besides
TNM stage – include LDH (lactate dehydrogenase) and
performance status [1, 2] while the tumour markers
S100 B protein and protein melanoma-inhibitory-activity
(MIA) are mostly used to detect progression of disease
but do not correlate directly with prognosis [3, 4].
Several studies have shown that eosinophil levels are
linked with prognosis in different tumour entities [5–7].
Increased frequencies of eosinophils were described to
predict a better outcome in primary small cell
oesophageal carcinoma and gastrointestinal, colorectal,
breast and prostate cancer [5, 8, 9]. However, patients
with eosinophilia show a worse prognosis in other
tumour entities such as Hodgkin’s lymphoma, oral squa-
mous cell carcinoma or cervical carcinoma [5, 6, 9–12].
Due to these inconsistent findings the role of eosinophils
in tumour control is still not fully understood [7, 9, 13].
Eosinophil count has already been shown to be a pre-
dictive biomarker for therapy with immune checkpoint
inhibitors in melanoma [14]. Baseline frequencies as well
as an increase of the number of eosinophils between the
first and the second infusion of the anti-CTLA-4 anti-
body ipilimumab correlate with a better overall survival
(OS) [14–16]. Regarding therapy with anti-PD-1 anti-
bodies, eosinophil count at baseline also correlated with
OS of melanoma patients [14, 17]. Additionally, recent
studies by our research group revealed the prognostic
value of eosinophils in melanoma patients [9]. A pro-
longed survival was demonstrated in both cohorts of mel-
anoma patients with eosinophilia, immunotherapy-naive
and in patients receiving immunotherapy [9]. However, in
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most cases patients only developed eosinophilia during
the course of metastatic disease, thus eosinophil count at
initial diagnosis of metastatic disease did not predict sur-
vival [9, 18].
Murine studies indicate that eosinophils are involved in
CD8+ T cell-mediated tumour rejection by producing che-
moattractants, such as CCL5, CXCL9 and CXCL10 [19].
Furthermore, studies on cancer patients also suggest that
eosinophilic granulocytes affect tumour cells directly
through the secretion of cytotoxic proteins [7, 19].
Eosinophil-derived neurotoxin (EDN), for example, is
associated with intratumoural cell apoptosis [7], but the
role of other eosinophilic cytotoxins, like eosinophil cat-
ionic protein (ECP), eosinophil peroxidase (EPO) or
major basic protein (MBP) is not clear yet [7, 20].
ECP serves as a ribonuclease and belongs to RNase A
family 3 [7, 12]. Its release can be induced by immuno-
globulins (IgE, IgG), surface-bound complement as well
as lipid mediators (lipopolysaccharides (LPS) or Lipid A)
[7, 12, 21]. Though ECP’s ribonucleolytic activity is low,
its cell membrane binding mediates a multitude of fur-
ther functions, like osmotic lysis, synthesis of reactive
oxygen species, reversed membrane asymmetry, chroma-
tin condensation as well as increased Caspase-3-like ac-
tivity and, thus, cytotoxicity as shown in mammalian cell
culture models [22]. It was suggested that ECP might,
aside from harming various microorganisms [7, 12, 22,
23], also have cytotoxic activity against cancer cells, such
as Hodgkin lymphoma and colorectal tumor cells [7, 12,
24–26], however, its definite role in human cancer is yet
to be investigated. In studies on oral squamous carcin-
oma cell lines, ECP did not just limit cell survival, but
induced morphological transformation, including vacu-
olation, formation of blebs and disabled cell adhesion
[24]. On the contrary, ECP was suggested to promote
tumour infiltration through muscle fiber corrosion [7].
According to in vitro experiments, ECP was involved in
degradation of membrane-associated cytoskeletal pro-
teins and myofibrillar proteins, such as myosin heavy
chain as well as α-actin [7]. Moreover, in vitro studies
showed that ECP inhibits immune functions such as the
production of immunoglobulins as well as T cell prolifer-
ation [7, 27]. However, the role of ECP in vivo has to be
determined.
This study investigates whether serum levels of ECP
have a prognostic value for patients with metastatic
melanoma.
Methods
Patients and clinical characteristics
In total, 56 patients with metastatic melanoma treated in
our clinic from January 2004 to September 2017 were
included in this study and analysed retrospectively. Vari-
ables that were analysed include gender, age, tumour
involvement, type of melanoma, systemic therapies, and
overall survival. The patient cohort incorporated patients
independently of their subsequent therapy. The patient
characteristics are depicted in Table 1, with p-values in-
cluded. The cohort included all histological types of mel-
anoma (cutaneous melanoma, mucosal melanoma, uveal
melanoma and melanoma of unknown primary). Due to
biological differences between mucosal/uveal and cuta-
neous melanoma, overall survival (OS) of patients with
cutaneous melanoma was analysed separately. Melan-
oma of unknown primary (MUP) was subsumed under
cutaneous melanoma. Blood sera routinely assessed for
tumour markers were used for analysis of eosinophil cat-
ionic protein (ECP). This retrospective study was exempt
from full application to the Ethics Committee, University
of Erlangen.
Determination of ECP in serum
For determination of ECP blood sera stored at − 20 °C
were thawed and measured by enzyme-linked immuno-
sorbent assay ELISA (Cusabio #CSB-E11729h) with a de-
tection range of 1.56–100 ng/ml according to
manufacturer’s protocol. Sera from the time at initial
diagnosis of metastatic melanoma were taken defining
the initial diagnosis as 0–6 months from the date of
stage IV diagnosis. Duplicates of each sample were mea-
sured. Serum levels of at least 16.0 ng/ml were defined
as elevated, because healthy individuals have a 95%
range from 2.3–15.9 ng/ml in the serum [28]. Addition-
ally, a cut-off of 12.2 ng/ml, as determined by recursive
partitioning, was analysed and correlated with survival.
Determination of LDH and blood counts
Serum lactate dehydrogenase (LDH) and blood counts
were routinely measured in our lab. LDH was analysed
by means of the LDH-ratio (actual value divided by the
upper limit of normal). Eosinophilia was defined as at
least 5% eosinophils in peripheral blood counts.
In 4 of 56 cases eosinophil counts were not analysed
at the time of serum assessment. In these patients the
eosinophil counts closest to the serum assessment was
taken i.e. a maximum of 4 months before or after.
Statistical methods
Event-time distributions were estimated with the
Kaplan-Meier method. Log–Rank (Mantel–Cox) test
was performed to determine the p-value. Cut-off values
were determined with recursive partitioning. For contin-
gency analyses Chi-square test and Fisher’s exact test
were utilised. Mann-Whitney test was used for nonpara-
metric tests. Univariate and multivariate analysis were
performed with Cox proportional hazard models. Graph-
ing was created using GraphPad Prism and R.
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Results
ECP is inversely correlated with survival
Patients with low ECP at initial diagnosis of metastatic
disease had a longer survival in comparison with pa-
tients with high ECP. With a cut-off at 16.0 ng/ml serum
ECP, the median OS for patients with ECP levels of at
least 16.0 ng/ml (n = 34) was 12months, compared with
28months for patients with levels below this threshold
(n = 22; p = 0.0916; Fig. 1a). A cut-off value of 16.0 ng/ml
was used since 95% of healthy individuals have ECP
values in the range from 2.3–15.9 ng/ml in the serum
[28]. Dichotomizing at 12.2 ng/ml, patients with higher
serum levels (n = 39) had a median OS of 12 months,
compared with 28months for patients below this thresh-
old (n = 17; p = 0.0642; Fig. 1b). In a subsequent analysis
the subgroup of uveal/mucosal melanoma with their dif-
ferent biology was excluded. The remaining patients
with cutaneous melanoma (n = 45) were analysed separ-
ately. Using a cut-off of 16.0 ng/ml, patients with ele-
vated ECP levels (n = 24) had a median OS of 12
months, compared with 28months for patients below
this threshold (n = 21; p = 0.0597; Fig. 2a). Dichotomizing
at 12.2 ng/ml, patients with lower ECP levels (n = 16)
showed a statistically significant longer OS (median OS
not reached) than patients with higher ECP levels (me-
dian OS 12 months; n = 29; p = 0.0393; Fig. 2b). Uveal
and mucosal melanoma patients were not analysed sep-
arately due to the small number of subjects, with 4 and
7 cases, respectively. Interestingly, 3 out of 4 uveal mel-
anoma patients and all mucosal melanoma patients (7/7)
were ECP high (cut-off: 16.0 ng/ml).
ECP and eosinophilia
In order to investigate whether occurrence of eosino-
philia (defined as at least 5% eosinophils in peripheral
blood) was linked to presence of ECP, eosinophil counts
in the course of the metastatic disease were analysed
and compared to ECP serum levels. From the patients
with decreased ECP serum levels (defined as < 16.0 ng/
ml, n = 22) at diagnosis of metastatic disease, only 9% (n
= 2) had eosinophilia at that time. Regarding the patients
with increased ECP levels (n = 34), eosinophilia was also
present in only 15% (n = 5) of the patients.Within the
patients with initially increased ECP levels, 47% (16/34)
had at some point during the course of their disease an
eosinophilia, whereas 32% (7/22) of the patients with de-
creased ECP also experienced one. In 4 of these 7 pa-
tients, blood sera at time of occurrence of eosinophilia
Table 1 Patient characteristics
Variables Patients with ECP higha (n = 34) Patients with ECP lowb (n = 22) p-value
Age Median (Range) 60 years (40–83 years) 64 years (31–90 years) 0.3877
OS Median (Range) 12 months (2–48 months) 28 months (3–44months) 0.0916
n % n %
Gender Male 22 65 14 64 0.9350
Female 12 35 8 36
Therapy Surgery 31 91 19 86 0.6701
Interferon-alpha 13 38 7 32 0.6245
Chemotherapy 29 85 13 59 0.0270
Radiotherapy 25 74 17 77 0.7520
Signal transduction inhibitor (targeted therapy) 21 62 9 41 0.1264
Checkpoint inhibitor therapy (immunotherapy) 9 26 18 82 < 0.0001
Type of melanoma Cutaneous 20c 59 12 55 0.7520
MUP 5 15 9 41 0.0270
Uveal 3 9 1 5 > 0.9999
Mucosal 7c 21 0 0 0.0349
LDH > ULN 20 59 18 82 0.0868
< ULN 14 41 4 18
BRAF statusd V600 mutation 13 38 9e 41 0.7151
V600 wildtype 14 41 12e 55
Brain metastases (M1d) 18 53 8 36 0.2244
adefined as > 16.0 ng/ml
bdefined as < 16.0 ng/ml
cone patient has both, cutaneous and mucosal melanoma
dBRAF status of 7 patients was not tested, BRAF test result of one patient was not evaluable
eone patient has discrepant test results of two distinct metastases one with V600E mutation and one with wildtype
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Fig. 1 a Overall survival of patients with metastatic melanoma (cut-off 16.0 ng/ml). Overall survival of melanoma patients depending on ECP level
(n = 56). Patients with an ECP level of 16.0 ng/ml or greater (n = 34) lived shorter (median OS = 12months) than patients with less than 16.0 ng/ml
serum ECP (n = 22; median OS = 28months; p = 0.0916) at the time of metastatic disease (stage 4). b Overall survival of patients with metastatic
melanoma (cut-off 12.2 ng/ml). Overall survival of patients with an ECP level of 12.2 ng/ml or greater (n = 39; median OS = 12months) and of
patients with less than 12.2 ng/ml serum ECP (n = 17; median OS = 28 months) at the time of stage 4 diagnosis within all melanoma patients
(n = 56; p = 0.0642)
Fig. 2 a Overall survival of patients with cutaneous melanoma (cut-off 16.0 ng/ml). Overall survival of patients with cutaneous melanoma
depending on ECP level (n = 45). Patients with an ECP level of 16.0 ng/ml or greater (n = 24) lived shorter (median OS = 12 months) than patients
with less than 16.0 ng/ml serum ECP (n = 21; median OS = 28 months; p = 0.0597) at the time of metastatic disease (stage 4). b Overall survival of
patients with cutaneous melanoma (cut-off 12.2 ng/ml). Overall survival of patients with an ECP level of 12.2 ng/ml or greater (n = 29; median OS
= 12 months) and of patients with less than 12.2 ng/ml serum ECP (n = 16; median OS not reached) at the time of stage 4 diagnosis within
patients having cutaneous melanoma (n = 45). The difference is statistically significant at p = 0.0393
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could be analysed as well. Interestingly, 75% (3/4) of
them still had decreased ECP levels when eosinophilia
peak was reached (average ECP value = 6.1 ng/ml). Only
in one patient, ECP serum levels exceeded the cut-off
(defined as 16.0 ng/ml), but still remained lower (35.7
ng/ml) than the average value of ECP levels of the pa-
tients with increased levels at diagnosis of metastatic
disease (46.8 ng/ml, n = 34).
Regarding development of eosinophilia after ECP as-
sessment, no significant difference (p = 0.2824) could be
found between patients with decreased ECP values and
patients with increased ECP values.
ECP is independent of LDH
In order to investigate the role of ECP as an independent
biomarker, we compared its serum levels in all patients
of our cohort with serum lactate dehydrogenase (LDH)
values, also taken at initial diagnosis of metastatic dis-
ease. As our statistical analysis shows, serum levels of
ECP are independent of serum lactate dehydrogen-
ase (Additional file 1). Coefficient of determination r2
was 0.026, meaning only 2.6% of the variation on ECP
levels can be explained by variations of LDH levels.
Treatments of the cohort
Subgroups of ECP low and ECP high were balanced with
respect to age and gender. Treatments of the two co-
horts were comparable (radiotherapy, surgery,
interferon-alpha) whereas differences were found in the
frequency of chemotherapy, immunotherapy and signal
transduction therapy (Table 1).
ECP as an independent prognostic biomarker
In order to identify potentially confounding variables,
Cox proportional hazard models were used for univari-
ate and multivariate analysis. Age and gender had no
influence on effect (Table 2). High ECP (cut-off: 16 ng/
ml) increases the risk for a death, whereas targeted ther-
apy as well as immunotherapy decrease this risk. The ef-
fect size of the influence of high ECP on survival is
diminished by subsequent treatment with targeted or
immunotherapy, but remains above 1 across all models
and thus represents a marker for a decrease of OS.
Discussion
This study suggests that ECP represents an independent
novel prognostic biomarker in patients with metastatic
melanoma. Patients with higher ECP levels at the time
of diagnosis of metastatic disease have a shorter survival
compared to patients with lower ECP serum levels. Re-
markably, survival difference was even more distinct in
the subgroup of patients with cutaneous melanoma or
MUP, excluding uveal and mucosal melanoma with their
different biology. Furthermore, nearly all patients with
uveal and mucosal melanoma showed elevated ECP
levels.
Interestingly, ECP was associated with a worse out-
come although it is secreted by eosinophils [7] whose
presence is positively correlated with OS in melanoma
[9]. This reverse correlation with survival was observed
irrespective of the kind of therapy the patients were re-
ceiving and irrespective of the presence of eosinophilia.
ECP’s reported cytotoxicity against cancer cells in vitro
[7, 12, 24–26] thus does not correspond to its disadvan-
tageous role in melanoma patients in vivo. Only Pereira
et al. hypothesized that ECP might promote tumour pro-
gression by supporting tumour infiltration of human
muscle tissue [7]. Given this unexpected finding of cor-
relation of ECP high with poorer survival further studies
in in vitro models and patient cohorts are required to
characterize the role of ECP.
Table 2 Adjusting for gender, age, targeted and immunotherapy (multivariate analysis)
(1) (2) (3) (4)
ECP > 16 1.869* (0.893, 3.913) 1.869* (0.893, 3.913) 1.873* (0.895, 3.918) 1.300 (0.578, 2.922)
gender 0.999 (0.482, 2.074) 0.987 (0.475, 2.053) 0.692 (0.311, 1.538)
age 1.006 (0.977, 1.035) 1.008 (0.978, 1.039)
Targeted therapy 0.728 (0.318, 1.663)
Immunotherapy 0.327** (0.130, 0.826)
Observations 56 56 56 56
R2 0.050 0.050 0.053 0.146
Max. Possible R2 0.982 0.982 0.982 0.982
Log Likelihood − 110.967 −110.967 −110.893 −107.992
Wald Test 2.760* (df = 1) 2.760 (df = 2) 2.900 (df = 3) 7.910 (df = 5)
LR Test 2.894* (df = 1) 2.894 (df = 2) 3.044 (df = 3) 8.846 (df = 5)
Score (Logrank) Test 2.841* (df = 1) 2.841 (df = 2) 2.985 (df = 3) 8.503 (df = 5)
Note: *p < 0.1; **p < 0.05
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Since ECP is a granule cytotoxic protein of eosinophils
[7], we would have assumed that eosinophilia precedes
high ECP serum levels. However, this was not the case
in our cohort. Only 15% of patients with elevated ECP
show eosinophilia compared to 9% with low ECP. In the
course of metastatic disease, 32% of patients with low
ECP and 47% of patients with elevated ECP experienced
eosinophilia. Thus, elevated levels of ECP are not dir-
ectly associated with the presence of eosinophilia.
Furthermore, there was no correlation of ECP with
LDH. Both, age and gender did not influence ECP’s ef-
fect size on OS. Importantly, all ECP values were mea-
sured at diagnosis of stage IV metastatic disease. It is
unclear why the ECP low group was subsequently
treated with immunotherapy more often. They were
however treated less often with targeted therapy. Tar-
geted as well as immunotherapy, as life prolonging ther-
apies, diminish ECP’s effect size on OS, but high ECP
levels still increase the risk of death when adjusting for
those variables. Possibly, there is a latent variable that is
connected to both, ECP and therapy, which has to be
further investigated.
Although the function of ECP in cancer progression or
rejection is still not fully understood, its levels were as-
sociated with prognosis in patients with metastatic mel-
anoma. So ECP seems to represent a novel independent
prognostic biomarker in melanoma and perhaps other
tumours as well. The measurement of this liquid bio-
marker in routine clinical practice would be easy and
time efficient. We are, therefore, currently validating
ECP as a new biomarker.
Conclusion
Pretreatment ECP levels, collected at the time of diagno-
sis of stage IV metastatic disease, are associated with
overall survival in melanoma patients. High serum ECP
correlates with a poor prognosis, independently of the
subsequent therapy.
ECP is a novel prognostic serum marker for the out-
come of melanoma patients, which is independent of
LDH and easy to perform in clinical practice. The nega-
tive prognostic value of high ECP level is unanticipated.
Additional file
Additional file 1: Correlation between pretreatment ECP and LDH
levels. (PNG 26 kb)
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